📋 Tender Overview
The participating health insurance funds aim to conclude discount agreements with all suitable pharmaceutical companies for the active ingredient combination Fluticasone/Vilanterol according to Section 130a, Paragraph 8 of the Social Code Book V. The contract will be concluded within the framework of the Open-House procedure of the participating funds: Individual negotiations on contract contents will not be conducted, and uniform conditions will apply. The participating health insurance funds do not guarantee exclusivity to individual contract partners. The contract duration is a maximum of 24 months starting from October 1, 2026, and will end no later than September 30, 2028, regardless of the contract conclusion date. In the event of patent expiration or market exclusivity expiration before the aforementioned end date, the contract will automatically terminate at the end of the month of patent expiration or market exclusivity expiration. Fluticasone, Vilanterol